Stocktoria

Denali Therapeutics Inc. DNLI

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-12-08 · LEI

Denali Therapeutics Inc. statistics & valuation

P / B4.0×
Return on capital-53.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
201720182019202020212022202320242025
Operating margin (%)
-35.90% -799.10% 18.70% -607.80% -314.20% -59.50% 201720182019202020212022202320242025
Return on equity (%)
-18.90% -6.60% -50.00% 6.20% -30.20% -31.30% -14.10% -34.40% -50.60% 201720182019202020212022202320242025
Shares outstanding
87.5M 94.7M 96.2M 120.5M 122.3M 136.0M 138.4M 164.5M 172.6M 201720182019202020212022202320242025
Net debt ($)
201720182019202020212022202320242025
Share buybacks ($)
201720182019202020212022202320242025
Return on assets (%)
-18.10% -5.50% -35.70% 4.40% -20.70% -22.30% -12.60% -30.80% -44.80% 201720182019202020212022202320242025
Free cash flow margin (%)
36.20% -635.30% 123.10% -451.90% -242.10% -112.20% 201720182019202020212022202320242025
Debt / equity (×)
201720182019202020212022202320242025
EPS ($)
-$0.39 -$2.07 $0.63 -$2.39 -$2.60 -$1.06 -$2.57 -$2.97 201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating margin-59.5%-314.2%-607.8%18.7%-799.1%-35.9%
Net margin-43.9%-300.6%-597.2%21.2%-740.7%-28.1%
FCF margin-112.2%-242.1%-451.9%123.1%-635.3%36.2%
Return on assets-44.8%-30.8%-12.6%-22.3%-20.7%4.4%-35.7%-5.5%-18.1%
Return on equity-50.6%-34.4%-14.1%-31.3%-30.2%6.2%-50.0%-6.6%-18.9%
Current ratio9.168.4613.653.772.3720.869.4814.6728.92

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.